BioCardia (BCDA) Competitors $3.14 +0.09 (+2.95%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. OSTX, NRXP, SRZN, ATHE, CVKD, PLUR, MRNS, KZR, ALXO, and ESLAShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include OS Therapies (OSTX), NRx Pharmaceuticals (NRXP), Surrozen (SRZN), Alterity Therapeutics (ATHE), Cadrenal Therapeutics (CVKD), Pluri (PLUR), Marinus Pharmaceuticals (MRNS), Kezar Life Sciences (KZR), ALX Oncology (ALXO), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. OS Therapies NRx Pharmaceuticals Surrozen Alterity Therapeutics Cadrenal Therapeutics Pluri Marinus Pharmaceuticals Kezar Life Sciences ALX Oncology Estrella Immunopharma OS Therapies (NYSE:OSTX) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Which has preferable valuation and earnings, OSTX or BCDA? OS Therapies has higher earnings, but lower revenue than BioCardia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOS TherapiesN/AN/A-$7.79MN/AN/ABioCardia$58K253.37-$11.57M-$3.09-1.02 Do analysts rate OSTX or BCDA? OS Therapies presently has a consensus price target of $18.00, indicating a potential upside of 786.70%. BioCardia has a consensus price target of $25.00, indicating a potential upside of 696.18%. Given OS Therapies' higher possible upside, research analysts clearly believe OS Therapies is more favorable than BioCardia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OS Therapies 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals have more ownership in OSTX or BCDA? 20.6% of BioCardia shares are owned by institutional investors. 13.8% of OS Therapies shares are owned by insiders. Comparatively, 20.0% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor OSTX or BCDA? BioCardia received 6 more outperform votes than OS Therapies when rated by MarketBeat users. However, 100.00% of users gave OS Therapies an outperform vote while only 60.71% of users gave BioCardia an outperform vote. CompanyUnderperformOutperformOS TherapiesOutperform Votes11100.00% Underperform VotesNo VotesBioCardiaOutperform Votes1760.71% Underperform Votes1139.29% Is OSTX or BCDA more profitable? OS Therapies has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. Company Net Margins Return on Equity Return on Assets OS TherapiesN/A N/A -569.57% BioCardia -1,999.77%N/A -208.38% Does the media favor OSTX or BCDA? In the previous week, BioCardia had 5 more articles in the media than OS Therapies. MarketBeat recorded 6 mentions for BioCardia and 1 mentions for OS Therapies. BioCardia's average media sentiment score of 1.56 beat OS Therapies' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OS Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioCardia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryBioCardia beats OS Therapies on 8 of the 14 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.70M$3.00B$5.57B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.7530.4222.4218.48Price / Sales253.37498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book-2.833.206.774.25Net Income-$11.57M-$72.35M$3.22B$248.23M7 Day Performance69.00%3.57%3.26%3.29%1 Month Performance12.14%0.17%0.02%2.42%1 Year Performance-45.92%-21.21%18.01%5.54% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.7229 of 5 stars$3.14+3.0%$25.00+696.2%-45.9%$14.70M$58,000.00-0.7540Short Interest ↓Positive NewsTrading HaltedOSTXOS Therapies1.9635 of 5 stars$1.49-2.6%$18.00+1,108.1%N/A$32.28MN/A0.00N/ANRXPNRx Pharmaceuticals2.4109 of 5 stars$1.87-3.1%$28.25+1,410.7%-17.8%$31.63MN/A-0.872Analyst ForecastNews CoveragePositive NewsSRZNSurrozen3.9133 of 5 stars$9.60-1.5%$38.50+301.0%+2.3%$31.50M$10.66M-0.4480Short Interest ↓Positive NewsATHEAlterity Therapeutics1.8287 of 5 stars$3.45-1.4%$12.00+247.8%+65.2%$30.59MN/A0.0010Short Interest ↑News CoveragePositive NewsCVKDCadrenal Therapeutics3.276 of 5 stars$16.18-3.4%$32.00+97.8%N/A$30.42MN/A-2.424Upcoming EarningsShort Interest ↓PLURPluri0.5781 of 5 stars$4.34+7.7%N/A-13.9%$30.37M$678,000.00-0.77150News CoverageGap UpHigh Trading VolumeMRNSMarinus Pharmaceuticals1.937 of 5 stars$0.55-0.2%$4.79+771.6%-61.1%$30.32M$30.99M-0.22110Upcoming EarningsAnalyst ForecastKZRKezar Life Sciences4.0311 of 5 stars$4.15-0.2%$39.50+851.8%-46.9%$30.32M$7M-0.3160Positive NewsALXOALX Oncology2.5269 of 5 stars$0.57+2.9%$4.14+631.2%-96.8%$30.23MN/A-0.1940ESLAEstrella Immunopharma3.035 of 5 stars$0.83+4.8%$16.00+1,823.1%+2.9%$30.09MN/A-3.20N/APositive NewsGap Up Related Companies and Tools Related Companies OSTX Alternatives NRXP Alternatives SRZN Alternatives ATHE Alternatives CVKD Alternatives PLUR Alternatives MRNS Alternatives KZR Alternatives ALXO Alternatives ESLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCDA Stock Free BCDA Stock Alerts